Differential Involvement of the P2Y₁ and P2Y_T Receptors in the Morphological Changes of Platelet Aggregation

Summary

The relative contributions of the P2Y₁ and P2Y_T receptors to the morphological changes induced in platelets by ADP or ADP-releasing agonists were assessed using two P2 antagonists, A2P5P and ARC67085, selective for P2Y₁ and P2Y_T, respectively. The P2Y₁ receptor was found to be involved in i) the centralization of secretory granules elicited by ADP, ii) the formation of filopodia induced by released ADP in weakly activated platelets and iii) actin polymerization and the cyto-skeletal translocation of cdc42, rac1 and rhoA, in an integrin _{IIb 3} dependent manner, in ADP-stimulated platelets. In contrast, the P2Y_T receptor was shown i) to be essential for the formation of stable macro-aggregates, ii) to enhance actin polymerization and the cytoskeletal translocation of small GTPases, probably through amplification of platelet aggregation, and iii) not to be involved in the early steps of platelet activation since its blockade did not affect the cytoskeletal translocation of rhoA.

Keywords

ADP receptors - platelet aggregation - morphology - cytoskeleton - GTPases

• References

• 1 Mills DC. ADP receptors on platelets. Thromb Haemost 1997; 76: 835-56.
• 2 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
• 3 Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP, and Gachet C. The P2Y1 receptor is necessary for ADP-induced platelet aggregation. Blood 1998; 92: 152-9.
• 4 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
• 5 Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
• 6 Bauer M, Retzer M, Wilde JI, Maschberger P, Essler M, Aepfelbacher M, Watson SP, Siess W. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 1999; 94: 1665-72.
• 7 Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-54.
• 8 Paul BZS, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signalling pathways. J Bio Chem 1999; 274: 28293-300.
• 9 Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor null mice. J Clin Invest 1999; 104: 1731-7.
• 10 Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in Gαq-deficient mice. Nature 1997; 389: 183-6.
• 11 Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial aggregation without shape change and potentiates collagen induced aggregation in the absence of Gαq. Blood 2000; 96: 2134-2139.
• 12 Herbert JM, Frehel D, Kiefer G, Guoy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98.
• 13 Humphries RG, Robertson MJ, Leff P. A novel series of P_2T purinoceptor antagonists: Definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-181.
• 14 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-66.
• 15 Daniel JL, Dangelmaier C, Lin L, Ashby B, Smith Kunapuli S. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-29.
• 16 Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1 activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
• 17 Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP, Mannucci PM. Deficiency of (³³P) 2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77: 986-90.
• 18 Xu Z, Afzelius B. Early changes in the substructure of the marginal bundle in human blood platelets responding to adenosine diphosphate. J Ultrastruct Mol Struct Res 1988; 99: 254-60.
• 19 Suzuki H, Kinlough-Rathbone RA, Packham MA, Mustard JF, Tanoue K, Yamazaki H. Localization of fibrinogen during ADP- or thrombin-induced aggregation of washed rabbit platelets. J Histochem Cytochem 1990; 38: 869-74.
• 20 Hensley MA, Frojmovic M, Taylor RG, Hantgan RR, Lewis JC. Platelet morphologic changes and fibrinogen receptor localization. Initial responses in ADP-activated human platelets. Am J Pathol 1992; 141: 707-19.
• 21 Nobes CD, Hall A. Rho, rac, cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62.
• 22 Hall H. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-14.
• 23 Cazenave JP, Hemmendinger S, Beretz A, Sutter-Bay A, Launay J. L’agrégation plaquettaire: outil d’investigation clinique et d’étude pharmacologique. Méthodologie. Ann Biol Clin 1983; 41: 167-79.
• 24 Martinson EA, Scheible S, Marx-Grunwitz A, and Presek P. Secreted ADP plays a central role in thrombin-induced phopholipase D activation in human platelets. Thromb Haemost 1998; 80: 976-81.
• 25 Paul BZS, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A_2-induced platelet aggregation. J Bio Chem 1999; 274: 29108-114.
• 26 Shattil SJ, Weisel JW, Kieber-Emmons T. Use of monoclonal antibodies to study the interaction between an integrin adhesion receptor, GP IIb-IIIa, and its physiological ligand, fibrinogen. Immunomethods 1993; 1: 53-63.
• 27 Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT. Ultrastructural studies of platelets aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: 1532-43.
• 28 Flaumenhaft R, Croce K, Chen E, Furie B, Furie BC. Protein of the exocytotic core complex mediate platelet alpha-granule secretion. Roles of vesicle-associated membrane protein, SNAP-23, and synthaxin 4. J Biol Chem 1999; 274: 2492-501.
• 29 Lemons PP, Chen D, Bernstein AM, Bennett MK, Whiteheart SW. Regulated secretion in platelets: Identification of elements of the platelets exocytosis machinery. Blood 1997; 90: 1490-500.
• 30 Hartwig JH, Bokoch GM, Carpenter LC, Janmey PA, Taylor LA, Toker A, Stossel TP. Thrombin receptor ligation and activated rac uncap actin filament barbed ends through phosphoinositides synthesis in permeabilized human platelets. Cell 1995; 82: 643-53.
• 31 Azim AC, Barkalow K, Chou J, Hartwig JH. Activation of the small GTPases, rac and cdc42, after ligation of the platelet PAR-1 receptor. Blood 2000; 95: 959-64.
• 32 Leng L, Kashiwagi H, Ren X-D, Shattil SJ. RhoA and the function of platelet integrin α_IIbβ3. Blood 1998; 91: 4206-15.
• 33 Schoenwaelder SM, Burridge K. Bidirectional signaling between the cyto-skeleton and integrins. Current Opinion in Cell Biology 1999; 11: 274-86.
• 34 Dash D, Aepfelbacher M, Siess W. Integrin II 3-mediated translocation of CDC42Hs to the cytoskeleton in stimulated human platelets. J Biol Chem 1995; 270: 17321-26.
• 35 Fox JEB. The platelet cytoskeleton. Thromb and Haemost 1993; 70: 884-93.